en
Scientific article
English

Severe complications after intrathecal methotrexate (MTX) for treatment of primary central nervous system lymphoma (PCNSL)

Published inClinical Neurology and Neurosurgery, vol. 106, no. 2, p. 82-87
Publication date2004
Abstract

Primary central nervous system lymphoma (PCNSL) is a rare and highly malignant tumor with increasing incidence. Survival has improved with the use of nonsurgical treatment modalities, of which methotrexate (MTX)-based intrathecal chemotherapy has been an important option. Here, we describe devastating complications in three patients with diffuse large B-cell lymphomas. After intrathecal MTX therapy two patients died secondary to fulminant brain edema. A third patient developed severe dementia, gait disturbance and urinary incontinence due to leukencephalopathy. Since bulky disease was present in all three patients, CSF flow may have been impaired. This might have exposed adjacent tissue to prolonged toxic drug concentrations. Regarding the severe complications seen in these patients, it is useful to consider high-dose intravenous MTX treatment only in periventricular PCNSL.

Keywords
  • Adult
  • Aged
  • Antimetabolites
  • Antineoplastic/administration & dosage/pharmacokinetics/toxicity
  • Brain Edema/chemically induced/pathology
  • Brain Neoplasms/drug therapy/pathology
  • Cerebral Ventricle Neoplasms/drug therapy/pathology
  • Cerebral Ventricles/drug effects/pathology
  • Dementia/chemically induced/pathology
  • Encephalocele/chemically induced/pathology
  • Endoscopy
  • Fatal Outcome
  • Female
  • Humans
  • Injections
  • Spinal
  • Lymphoma
  • B-Cell/drug therapy/pathology
  • Lymphoma
  • Large B-Cell
  • Diffuse/drug therapy/pathology
  • Magnetic Resonance Imaging
  • Male
  • Methotrexate/administration & dosage/pharmacokinetics/toxicity
  • Middle Aged
  • Temporal Lobe/pathology
  • Tomography
  • X-Ray Computed
Affiliation Not a UNIGE publication
Citation (ISO format)
WEIGEL, Ralf et al. Severe complications after intrathecal methotrexate (MTX) for treatment of primary central nervous system lymphoma (PCNSL). In: Clinical Neurology and Neurosurgery, 2004, vol. 106, n° 2, p. 82–87. doi: 10.1016/j.clineuro.2003.09.005
Main files (1)
Article (Published version)
accessLevelRestricted
Identifiers
ISSN of the journal0303-8467
271views
0downloads

Technical informations

Creation04/08/2019 3:12:00 PM
First validation04/08/2019 3:12:00 PM
Update time03/15/2023 4:06:51 PM
Status update03/15/2023 4:06:50 PM
Last indexation01/17/2024 5:17:33 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack